StockNews.com began coverage on shares of Galectin Therapeutics (NASDAQ:GALT – Get Rating) in a research report sent to investors on Friday morning. The firm issued a hold rating on the stock. Separately, HC Wainwright restated a buy rating and issued a $11.00 price target on shares of Galectin Therapeutics in a research note on Friday, […]